Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation
Chemical Biology & Drug Design · 2026-03 · 107 (3)
DOI: 10.1111/cbdd.70280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 26.03.2026. Verfasst von Aisha A Alsfouk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents, Thiadiazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Princess Nourah Bint Abdulrahman University.
Abstract (Originalsprache)
In this study, a series of novel thiadiazole derivatives ( 7a , 7b , 9a , 9b , and 9c ) were rationally designed as potential VEGFR‐2 inhibitors using a pharmacophore‐guided strategy. The compounds were synthesized and assessed for their antiangiogenic and anticancer effects. Among them, compound 9b showed the strongest VEGFR‐2 inhibition (IC 50 = 0.030 ± 0.001 μM), outperforming the reference drug Sorafenib. Cytotoxicity tests revealed that 9b was highly effective against MCF‐7 breast cancer cells (IC 50 = 8.06 ± 0.7 μM) while exhibiting minimal toxicity toward normal WI‐38 cells. Flow cytometry demonstrated that 9b induced significant G2/M cell cycle arrest and increased apoptosis, supported by molecular data showing upregulation of caspase‐3 and Bax and downregulation of Bcl‐2, indicating activation of the intrinsic apoptotic pathway. Extensive in silico studies—including molecular docking, 200 ns molecular dynamics simulations, interaction mapping, principal component analysis of trajectories, and free energy landscape analysis—confirmed that 9b binds stably and efficiently within the VEGFR‐2 active site. Overall, these results highlight compound 9b as a promising VEGFR‐2‐targeted antiangiogenic agent with potent enzymatic and cellular activity, favorable selectivity, and mechanistic validation through combined experimental and computational approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Department of Chemistry, Faculty of Science, Al-Azhar University, Cairo, Egypt.
- Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
- Chemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
ORCID-Profile: Aisha A Alsfouk, Hazem Elkady, Walid E Elgammal, Hazem A Mahdy, Ibrahim H Eissa, Ahmed M Metwaly
Förderung
- Princess Nourah Bint Abdulrahman University
Zitieren
APA
Alsfouk, A. A., Elkaeed, E. B., Elkady, H., Elgammal, W. E., Mahdy, H. A., Nofal, A., Eissa, I. H., Husein, D. Z., Ibrahim, I. M., Elkotamy, M. S., & Metwaly, A. M. (2026). Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation. Chemical Biology & Drug Design, 107(3). https://doi.org/10.1111/cbdd.70280
Vancouver
Alsfouk AA, Elkaeed EB, Elkady H, Elgammal WE, Mahdy HA, Nofal A, et al. Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation. Chemical Biology & Drug Design. 2026;107(3). doi:10.1111/cbdd.70280
BibTeX
@article{Alsfouk2026,
author = {Alsfouk, Aisha A and Elkaeed, Eslam B and Elkady, Hazem and Elgammal, Walid E and Mahdy, Hazem A and Nofal, Ahmed and Eissa, Ibrahim H and Husein, Dalal Z and Ibrahim, Ibrahim M and Elkotamy, Mahmoud S and Metwaly, Ahmed M},
title = {Thiadiazole‐Derived VEGFR ‐2 Inhibitors: From Design to Anticancer Evaluation},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {3},
doi = {10.1111/cbdd.70280}
}
EUVIMED